Why the study?
Does combined erythropoietin and iron therapy reduce red cell transfusion rates in anaemic patients undergoing transcatheter aortic valve implantation?
Does combined erythropoietin and iron therapy reduce red cell transfusion rates in anaemic patients undergoing transcatheter aortic valve implantation?
Pre-procedural administration of erythropoietin and iron does not reduce the rate of red cell transfusions in anemic patients undergoing TAVI.
Answers are grounded in this paper and cite their sources.
Discourages the routine use of pre-procedural erythropoietin and iron to prevent.
AIMS: The aim of this study was to evaluate, in anaemic patients, the efficacy of erythropoietin (EPO) in reducing red cell (RC) transfusion rates post TAVI. METHODS AND RESULTS: This was a randomised double-blind trial. Patients with severe symptomatic aortic stenosis and concomitant anaemia with an indication for TAVI were randomised (1:1) to receive two weight-based doses of EPO (darbepoetin alfa)+iron or placebo at days 10 (±4 days) and 1 (±1 day) pre TAVI. The primary outcome was the rate of RC transfusions at 30 days. A total of 100 patients (mean age 81±7 years, male 49%) were included: 48 patients received EPO (+iron) and 52 patients received placebo. Baseline characteristics and procedural findings were well balanced between groups except for baseline haemoglobin levels, which were lower in those patients receiving EPO (10.7±1.2 vs. 11.3±1.1 g/dl, p=0.01). The rate of 30-day RC transfusion was similar in both groups (27.1 vs. 25.0% in the EPO and placebo groups, respectively; adjusted odds ratio 1.05, 95% CI: 0.42-2.64, p=0.92), and no differences were observed in the number of RC units per transfused patient (1 [1-3] vs. 2 [1-2] in the EPO and placebo groups, respectively, adjusted p=0.99). Rates of 30-day mortality, stroke, new-onset atrial fibrillation, acute kidney injury, and troponin peak were also similar between groups (p>0.20 for all). CONCLUSIONS: EPO (+iron) administration failed to reduce RC transfusion rates or the per-patient number of transfusion units in anaemic patients undergoing TAVI.
No takes yet. Share an insight, caveat, or question.
Ureña et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: